Skip to content
Axcess News – Lifestyle
Author:
Actuate Therapeutics
Actuate to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib
September 9, 2026
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
June 9, 2026
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 11, 2026
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
May 7, 2026
Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
April 15, 2026
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
March 5, 2026
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
March 4, 2026